Myomo - MYO Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MYO shares.
View MYO analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price objectives for Myomo's stock. Their MYO share price forecasts range from $6.70 to $17.00. On average, they expect the company's share price to reach $11.85 in the next year. This suggests a possible upside of 581.0% from the stock's current price.
View analysts price targets for MYO or view top-rated stocks among Wall Street analysts.

Myomo saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 27,100 shares, an increase of 24.9% from the July 15th total of 21,700 shares. Based on an average daily trading volume, of 68,100 shares, the short-interest ratio is currently 0.4 days. Currently, 0.4% of the company's stock are short sold.
View Myomo's Short Interest.

Myomo, Inc. (NYSEAMERICAN:MYO) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.10. The firm had revenue of $4.38 million for the quarter, compared to analyst estimates of $3.13 million. Myomo had a negative net margin of 65.87% and a negative trailing twelve-month return on equity of 81.23%.

Myomo issued an update on its second quarter 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.40 million-$3.60 million, compared to the consensus revenue estimate of $4.54 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL).

Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."

Myomo's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.35%). Insiders that own company stock include David A Henry, Paul R Gudonis and Thomas Aloysius Jr Crowley.
View institutional ownership trends.

Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYO stock can currently be purchased for approximately $1.74.

Myomo (NYSEAMERICAN:MYO) has a market capitalization of $12.18 million and generates $13.86 million in revenue each year. The company earns $-10,370,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The official website for the company is myomo.com. The company can be reached via phone at (617) 996-9058 or via email at ir@myomo.com.